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Abstract
Background: Non-neuronal cells, such as microglia and lymphocytes, are thought to be involved in the
pathogenesis of amyotrophic lateral sclerosis (ALS). Previous studies have demonstrated neuroprotective effects of
lymphocytes at the end stage of ALS, partly through induction of alternatively activated microglia (M2 microglia),
which are neuroprotective. In this study, we investigated the role of lymphocytes in the early stage of the disease
using an animal model of inherited ALS.
Methods: We established a transgenic mouse line overexpressing the familial ALS-associated G93A-SOD1 mutation
(harboring a single amino acid substitution of glycine to alanine at codon 93) with depletion of the Rag2 gene
(mSOD1/RAG2-/- mice), an animal model of inherited ALS lacking mature lymphocytes. Body weights, clinical
scores and motor performance (hanging wire test) of mSOD1/RAG2-/- mice were compared to those of mutant
human SOD1 transgenic mice (mSOD1/RAG2+/+ mice). Activation of glial cells in the spinal cords of these mice
was determined immunohistochemically, and the expression of mRNA for various inflammatory and anti-
inflammatory molecules was evaluated.
Results: Clinical onset in mSOD1/RAG2-/- mice was significantly delayed, and the number of lectin-positive cells in
spinal cord was increased at the early stage of disease when compared to mSOD1/RAG2+/+ mice. Quantitative RT-
PCR confirmed that mRNA for Ym1, an M2 microglial-related molecule, was significantly increased in mSOD1/
RAG2-/- mouse spinal cords at the early disease stage.
Conclusions: Compared with mSOD1/RAG2+/+ mice, mSOD1/RAG2-/- mice displayed delayed onset and
increased M2 microglial activation at the early stage of disease. Thus, lymphocytes at the early pathological phase
of ALS display a deleterious effect via inhibition of M2 microglial activation.
Background
Amyotrophic lateral sclerosis (ALS) is characterized by a
progressive degeneration of motor neurons in brain and
the spinal cord, resulting in muscle weakness. Patients
eventually become paralyzed and approximately 50% die
within 3 years of onset of symptoms, usually as the result
of respiratory failure [1]. Although the precise
mechanisms of ALS remain unclear, approximately 2% of
patients with ALS have dominant mutations in the Cu/
Zn superoxide dismutase 1 (SOD1) gene [2]. Transgenic
mice overexpressing the mutant human SOD1 gene
(mSOD1 mice) develop progressive motor neuron degen-
eration that resembles ALS and therefore these mice
serve as an appropriate animal model for the disease [3].
Although ALS is characterized by motor neuron degen-
eration, activation of microglia and astrocytes and infil-
tration of T lymphocytes are significant pathological
hallmarks in the spinal cord lesions of ALS patients and
mSOD1 mice, and a role for these cells in the pathogen-
esis of ALS has been suggested [4-6]. Recent experiments
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but rather that the process is non-cell-autonomous and
depends on the active participation of non-neuronal
cells, such as microglia, astrocytes, and T cells [7-9].
Microglia, resident immune effector cells in the cen-
tral nervous system (CNS), display functional plasticity
during activation, which involves changes in cell num-
ber, morphology, surface receptors, and production of
growth factors and cytokines [10]. T-cell-derived cyto-
kines play critical roles in the control of the microglial
phenotype. For example, classically activated microglia
(M1 microglia) differentiate in response to granulocyte
macrophage colony-stimulating factor (GM-CSF) and
are primed by interferon gamma (IFN-g), one of the
most important cytokines produced by T helper 1 (Th1)
cells, in the presence of lipopolysaccharide (LPS)
[10,11]. M1 microglia secrete increased proinflammatory
cytokines, superoxide radicals, nitric oxide (·NO), and
reduced neurotrophic factors, which promote neuronal
death [12]. In contrast, representative T helper 2 (Th2)
cytokines, such as interleukin 4 (IL-4) and interleukin
13 (IL-13), can convert microglia, primed by macro-
phage colony-stimulating factor (M-CSF), to an alterna-
tively activated M2 phenotype [12]. M2 microglia are
also characterized by increased expressions of arginase 1
(Arg1), resistin-like alpha (Retnla), and chitinase 3-like 3
(Ym1), which play important roles in tissue repair and
remodeling [10]. However, the precise roles of crosstalk
between T cells and microglia in the pathology of ALS
remain unknown.
In this study, we established mSOD1 mice lacking
recombination-activating gene 2 (mSOD1/RAG2-/-), an
animal model for inherited ALS that lacks mature lym-
phocytes, and compared their phenotype and microglial
characteristics with that of mutant human SOD1 trans-
genic mice (mSOD1/RAG2+/+). The clinical onset of
mSOD1/RAG2-/- mice was significantly delayed com-
pared to the control group. Consistent with this,
increased numbers of activated microglia/macrophages
and the expression of Ym1, a molecule with matrix
reorganization and wound-healing effects [13,14], were
observed at the early stage of the disease in mSOD1/
RAG2-/- mice compared to mSOD1/RAG2+/+ mice.
These results suggest an important role for lymphocytes
interacting with microglia in the early phase of neurode-
generation in ALS.
Methods
Animals
All mice were housed in microisolator cages within a
modified pathogen-free barrier facility at the Animal
Resource Center for Infectious Diseases, Research Insti-
tute for Microbial Diseases, Osaka University. All ani-
mals had free access to food and water ad libitum,a n d
all of the experimental procedures followed our institu-
tional guidelines.
Transgenic mice overexpressing the familial ALS-asso-
ciated G93A SOD1 mutation (harboring a single amino
acid substitution of glycine to alanine at codon 93)
(mSOD1 mice) were obtained from The Jackson Labora-
tory (Bar Harbor, ME) (strain designated: B6SJL-TgN
(SOD1-G93A)1Gurd/J) and were backcrossed with
C57BL/6 mice for at least 10 generations. Transgenic
progeny were identified by a polymerase chain reaction
(PCR) of genomic DNA using specific primers for exon
4o ft h eh u m a nS O D 1g e n e :e x 4 P l a5 ’-CATCAGCCC-
TAATCCATCTGA-3’ and ex4P2a 5’-TGGATCTTA-
GAATTCGCGAC-3’. PCR conditions included 35 cycles
at 94°C for 30 s, 60°C for 30 s and 72°C for 1 min. The
PCR products were resolved on a 1.0% agarose/ethidium
bromide gel and photographed under UV illumination.
RAG2-/- mice on a C57BL/6 background were
obtained from The Jackson Laboratory. RAG2-/- mice
were initially bred with mSOD1 mice. The presence or
absence of the RAG2 gene was determined by PCR using
250 ng of tail DNA. The following primers were: Rag A,
5’-TAAAAGACCTATTCACAATCAAAAATGTCC-3’;
and Rag B, 5’-TCAATCGTGTTGTCCCCTAGAGAGA-
CAAGG-3’. PCR products for the different mice include:
a 1100-bp band for homozygote mice, 1100- and 917-bp
bands for heterozygote mice, and a 917-bp band for
wild-type. PCR was conducted with 35 cycles at 94°C
for30 s, 60°C for 30 s and 72°C for 1 min. The PCR
products were resolved by 1.0% agarose/ethidium bro-
mide gel electrophoresis and photographed under UV
illumination.
Symptomatic analysis and hanging-wire test
Symptomatic analysis and weight measurements of male
mice were conducted every 3-4 days starting at day 64 (n =
13 for mSOD1/RAG2+/+ mice, n = 11 for mSOD1/
RAG2-/- mice). Animals were scored for motor symptoms
using a 4-point scoring system as follows: 4 points, normal
(no sign of motor dysfunction); 3 points, hind limb tremors
were evident when suspended by the tail; 2 points, gait
abnormalities were present; 1 point, dragging of at least
one hind limb; and 0 points, inability to right self within 30
s. Onset was defined retrospectively as the earliest time
when the mice showed symptoms (i.e., score < 4).
For the hanging-wire test, each male mouse was
placed on a wire lid of a conventional housing cage. The
lid was shaken gently to prompt the mouse to hold onto
t h eg r i db e f o r et h el i dw a ss w i f t l yt u r n e du p s i d ed o w n .
The latency until the mouse let go with at least both
hind limbs was timed. Each mouse was allowed up to
three attempts to hold on to the inverted lid for an arbi-
t r a r ym a x i m u mo f9 0sa n dt h el o n g e s tl a t e n c yw a s
recorded.
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astrocytes
Mice were anesthetized with an overdose of pentobarbi-
tal (60 mg/kg i.p.) and transcardially perfused with ice-
cold 4% paraformaldehyde. Spinal cords were dissected
out, postfixed in the same fixative for 4 h, placed over-
night in 30% sucrose, and embedded in O.C.T. Com-
pound (Sakura Finetek, Tokyo, Japan). Sections were
frozen in liquid nitrogen and the blocks were stored at
-80°C until use. Ten-micrometer-thick transverse sec-
tions of spinal cords were prepared using a Leica 3050 S
cryostat (Thermo Shandon, Inc., Pittsburgh, PA) and
collected onto Superfrost slides (Matsunami Glass
Industries, Ltd., Osaka, Japan).
For lectin staining, sections were permeabilized with
0.2% Tween-20 in 0.05 M Tris-buffered saline (TBST,
pH 7.2) for 10 min. They were then incubated with
FITC-conjugated lectin (Sigma, St. Louis, MO) diluted
1:750 in phosphate-buffered saline (PBS) overnight at 4°
C. Sections were washed 3 times in 0.2% TBST for 5
min, and mounted with VECTASHIELD Mounting
Medium with DAPI (Vector Laboratories, Burlingame,
CA). The fluorescence-labeled sections were examined
using a LSM 510 confocal microscope (Zeiss, Thorn-
wood, NY).
For immunohistochemistry, sections were permeabi-
lized with 0.2% TBST for 10 min and pretreated with
10% normal goat serum (Jackson ImmunoResearch
Laboratories, West Grove, PA) for 1 h at RT to block
non-specific IgG binding. Sections were then incubated
with rabbit anti-mouse glial fibrillary acidic protein
(GFAP) antibody (Ab) (1:1000) (Dako, Carpinteria, CA)
overnight at 4°C. As a negative control, the primary Ab
was omitted during the reaction. After rinsing with 0.2%
TBST 3 times, sections were incubated with Cy5-conju-
gated F(ab’) 2 fragment donkey anti-rabbit IgG (1:500 in
PBS) for 3 h at RT. Sections were then washed 3 times
in 0.2% TBST for 5 min and mounted with VECTA-
SHIELD Mounting Medium with DAPI (Vector Labora-
tories). The fluorescence-labeled sections were examined
using an LSM 510 confocal microscope (Zeiss).
For quantification of microglia and astrocytes, we ana-
lyzed the density of lectin- or GFAP-positive cells,
respectively, in every third sample section of lumbar
horizontal spinal cord sections. A total of 25 sections
were analyzed and cell densities were counted in 4 ran-
domly selected fields per section (a total of 100 fields).
Western blots
Mice were anesthetized with an overdose of pentobarbi-
tal (60 mg/kg i.p.) and transcardially perfused with ice-
cold PBS. Dissected spinal cords were homogenized
with protease inhibitors and loaded onto 10% SDS-
PAGE gels. Blots were incubated with an antibody
against Iba-1 (Wako, Richmond, VA) and visualized by
chemiluminescence.
Quantitative RT-PCR
RNA was isolated from homogenized flash-frozen mice
spinal cords using TRIzol (GIBCO/BRL, Grand Island,
NY) and purified using RNeasy (QIAGEN, Valencia,
CA) according to the manufacturer’s recommendations.
The concentrations were determined spectrophotometri-
cally. cDNA was generated from 100 ng of each RNA
sample digested with RNase-free DNase I (QIAGEN)
and SuperScript VILO cDNA Synthesis Kit (Invitrogen,
Carlsbad, CA) according to the manufacturer’s recom-
mendations. The synthesized cDNA was amplified with
SYBR Premix Ex Taq II (Takara Bio Inc., Shiga, Japan)
and the primer set, which is listed below, using the Ste-
pOnePlus real-time PCR system (Applied BioSystems,
F o s t e rC i t y ,C A ) .P r i m e rs e t su s e di nt h i ss t u d yw e r e :
glyceraldehyde-3-phosphate dehydrogenase (GAPDH):
5’-TGTGTCCGTCGTGGATCTGA-3’ and 5’-TTGC
TGTTGAAGTCGCAGGAG-3’; nitric oxide synthase 2
(NOS2): 5’-GCAGAGATTGGAGGCCTTGTG-3’ and
5’-GGGTTGTTGCTGAACTTCCAGTC-3’;I F N - g:5 ’-
CGGCACAGTCATTGAAAGCCTA-3’ and 5’-GTTGCT
GATGGCCTGATTGTC-3’;Y m 1 :5 ’-TTTGATGGCCT-
CAACCTGGA-3’ and 5’-AGTGAGTAGCAGCCTTG-
GAATGTC-3’; Retnla: 5’-TCAGCAATCCCATGGCGT
ATAA-3’ and 5’-TCATCAGTATTCACTGGGACCAT
CA-3’; glial cell line derived neurotrophic factor
(GDNF): 5’-CCCACGTTTCGCATGGTTC-3’ and 5’-TG
GGCAGCTGAGGTTGTCAC-3’; solute carrier family 1
(glial high affinity glutamate transporter), member 3
(SLC1A3): 5’-CTTGTCTCATCCATTGGCCTCA-3’ and
5’-CCATTCCCAATAAGTGTCCTGTCTG-3’;M a n n o s e
receptor, C type 1 (MRC1): 5’-TCGAGACTGCTGCTG
AGTCCA-3’ and 5’-AGACAGGATTGTCGTTCAAC
CAAAG-3’;M - C S F :5 ’-GAACAGCCTGTCCCATC
CATC-3’ and 5’-TGAGGCCAGCTCAGTGCAA-3’;
GM-CSF: 5’-AAGGGCGCCTTGAACATGAC-3’ and
5’-AAATCCGCATAGGTGGTAACTTGTG-3’;i n t e r -
feron gamma receptor 1 (IFN-gR): 5’-TGACGGGAGC
ACCTGTTACAC-3’ and 5’-TTTCGACCGTATGTTTC
GTATGTAG-3’;I L - 4 :5 ’-TCTCGAATGTACCAGGA
GCCATATC-3’ and 5’-AGCACCTTGGAAGCCCTA-
CAGA-3’; interleukin 4 receptor, alpha (IL-4R): 5’-TGA
GCCCGTGGTATCTGCAA-3’ and 5’-CCAGATCCCT
GTGCCTCAAAC-3’; IL-13: 5’-CAATTGCAATGCCAT
CTACAGGAC-3’ and 5’-CGAAACAGTTGCTTTGTG-
TAGCTGA-3’; interleukin 13 receptor alpha 1 (IL-13R):
5’-CAGTCTTGCAGCATGGGAACA-3’ and 5’-TGAGT
CCCTAAGGCCTGGAGATTAC-3’. A standard thermal
cycling program was used for all PCRs: 95°C for 60 s, 40
cycles of 95°C for 5 s, and 60°C for 30 s. The relative
expression levels of each mRNA were calculated using
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to the control samples.
Statistical Analyses
Differences in onset and survival (Figure 1B and 1E)
were computed using Kaplan-Meier survival statistics
(generalized Wilcoxon test). Data in Figure 1A, C and
1D were analyzed using a two-way repeated ANOVA.
All other data were analyzed using an unpaired two-
tailed Student’s t test using Excel software (Microsoft,
Dedmond, WA). Data are expressed as mean ± SEM. p
< 0.05 was considered statistically significant. Results
Delayed clinical onset in mutant SOD1 transgenic mice
deficient in RAG2
To investigate the role of lymphocytes in ALS, mSOD1
mice were crossed with RAG2-/- mice to generate
mSOD1/RAG2-/- mice that lack functional T- and B-lym-
phocytes. Although there were no differences in relative
copy number of mSOD1 (data not shown), delayed clinical
onset was observed in mSOD1/RAG2-/- mice when com-
pared with mSOD1/RAG2+/+ mice (p = 0.0033) (Figure
1A and 1B) or mSOD1/RAG2+/- mice (mSOD1/RAG2+/-
mice: 94 ± 4 days (n = 8); mSOD1/RAG2-/- mice: 118 ± 3
days (n = 11), p = 0.0007, generalized Wilcoxon test).
Next, neuromuscular dysfunction in mSOD1 mice was
evaluated with the hanging-wire test twice a week. Consis-
tent with the clinical onset and scores, genetic depletion of
lymphocytes significantly improved motor function of
mSOD1/RAG2-/- mice during the early stage (p = 0.0043)
(Figure 1C). As neurodegeneration in mSOD1 mice is
accompanied by loss of body weight, we also measured the
body weight of these mice. We found that mSOD1/
RAG2-/- mice had increased weight gain compared to
mSOD1/RAG2+/+ mice, suggesting alleviated neurode-
generation in mSOD1/RAG2-/- mice (p = 0.0457) (Figure
1D). mSOD1/RAG2+/+ mice had normal numbers of
white blood cells and normal ratios of T and B lympho-
cytes (white blood cell count: mSOD1tg 8067 ± 1324/ul,
control 10867 ± 1629/ul, percentage of CD3
+ cells:
mSOD1tg 32.00 ± 1.21%, control 31.18 ± 1.23%, percen-
tage of B220
+ cells: mSOD1tg 55.97 ± 2.19%, control 57.85
± 1.52%, n = 4 for each group). Although the absence of
mature lymphocytes delayed onset of the disease, it did
not affect the survival of mSOD1 mice (Figure 1E) (p =
0.13). Furthermore, survival times for mSOD1/RAG2+/-
mice were comparable to those of mSOD1/RAG2-/- mice
(average survival time; mSOD1/RAG2+/- mice: 142 ± 3
days (n = 8); mSOD1/RAG2-/- mice: 142 ± 3 days (n =
11), p = 0.74, generalized Wilcoxon test). Collectively,
these results suggest that lymphocytes may contribute to
acceleration of neurodegeneration in mSOD1 mice at the
early stage.
Increased microglial activation at the early stage in
mSOD1 mice without mature lymphocytes
Neurodegeneration in ALS is accompanied by micro-
glial-mediated neuroinflammation, which greatly affects
disease progression [12]. Persistent activation of micro-
glia is achieved by the sustained production of various
cytokines induced by T lymphocytes [10]. To assess
whether the absence of lymphocytes affects activation of
microglia/macrophages in mSOD1 mice, spinal cord
sections were stained with lectin. Lumbar spinal cord
sections from early stage (70-90 days of age) mSOD1/
RAG2-/- mice showed significantly increased numbers
of lectin-positive microglia/macrophages compared with
mSOD1/RAG2+/+ mice. However, there was no signifi-
cant difference in the number of these cells between
mSOD1/RAG2-/- mice and mSOD1/RAG2+/+ mice at
the end stage of disease (130-150 days of age) (Figure
2A and 2B). Consistent with these results, western blot
analysis showed an intense band for Iba-1 at the early
stage of disease in spinal cord of mSOD1/RAG2-/- mice
(Figure 2C). However, this striking difference disap-
peared at the end stage.
Astrocytes are the most abundant non-neuronal cells
in the CNS and their important roles in neurodegenera-
tive disease have been suggested [8,9]. To assess the
relevance of astrocytes, GFAP-immunoreactive cells
were evaluated in lumbar spinal cords. At both early
and end stages, there were no differences in intensity of
GFAP immunoreactivity (IR) between mSOD1/RAG2-/-
mice and control mice (Figure 3A). Also, both groups
had comparable numbers of GFAP positive cells (Figure
3B). Collectively, these results suggest that mature lym-
phocytes may play a role in the inhibition of microglial
activation but not of astrocyte activation.
Increased mRNA expression of Ym1, a neuroprotective
factor, in mSOD1/RAG2-/- mice at the early stage
Activation of microglia in the presence of GM-CSF and
IFN-g results in a classically activated phenotype (M1
microglia) characterized by the production of ·NO [11].
The primary function of M1 microglia is thought to be
activation of inflammation and tissue injury, whereas
microglia activated alternatively (M2 microglia) by M-
CSF, IL-4 and IL-13 express mannose receptor, MHC
class II and Ym1, which leads to resolution of inflamma-
tion and promotion of wound healing [10,11]. To deter-
mine if delayed onset in mSOD1/RAG2-/- mice is
attributable to increased numbers of M2 microglia, we
evaluated the mRNA expression of M2 microglial target
genes in spinal cord of mSOD1/RAG2-/- mice and con-
trol mice. Quantitative RT-PCR demonstrated that
mRNA expression of Ym1, which is induced by activated
M2 microglia/macrophages, was significantly elevated in
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Figure 1 Delayed clinical onset in male mutant SOD1 transgenic mice deficient in the RAG2 gene. (A) Disease progression was
significantly delayed in mSOD1/RAG2-/- mice (filled circles; n = 11) compared with mSOD1/RAG2+/+ mice (open circles; n = 13). (B) Kaplan
Meier curve for symptomatic onset in mSOD1/RAG2+/+ mice (n = 13) and mSOD1/RAG2-/- mice (n = 11). Mice were evaluated for signs of
motor deficiency with the following 4-point scoring system: 4 points, normal (no sign of motor dysfunction); 3 points, hind limb tremors were
evident when suspended by the tail; 2 points, gait abnormalities were present; 1 point, dragging of at least one hind limb; 0 points, inability to
right self within 30 s. We defined the point when the clinical score became 3 as being clinical onset. The mSOD1/RAG2-/- mice exhibited the
disease phenotype at a later stage than the mSOD1/RAG2+/+ mice. (C) Time course of motor performance in the hanging-wire test. mSOD1/
RAG2-/- mice (n = 11) performed significantly better than mSOD1/RAG2+/+ mice (n = 13). (D) Changes in mean body weight of mSOD1/
RAG2-/- mice (n = 11) and mSOD1/RAG2+/+ mice (n = 13). (E) Kaplan-Meier survival curve. Absence of T and B cells did not affect the survival
of mSOD1 mice (mSOD1/RAG2+/+ mice; n = 13, mSOD1/RAG2-/- mice; n = 11) (p = 0.13). Data are expressed as the mean ± SEM. Statistical
analysis was done using the generalized Wilcoxon test for Kaplan-Meier curves (B,E) and a two-way repeated multivariate ANOVA (A, C, D) during
12 to 16 weeks of age. *:p < 0.05, #:p < 0.005.
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Figure 2 Significantly increased lectin-positive cells at the early stage of disease. (A) Lumbar sections of spinal cord from mSOD1/RAG2-/-
and mSOD1/RAG2+/+ mice at early (70-90 days of age) and end (130-150 days of age) stage of disease were stained for lectin (microglia/
macrophage). Scale bar = 50 μm. (B) Significantly increased numbers of lectin-positive microglia/macrophages are observed at the early stage of
the disease in spinal cord sections of mSOD1/RAG2-/- mice compared with mSOD1/RAG2+/+ mice. There was no significant difference in the
number of lectin-positive cells at the end stage of disease. Significance was evaluated by using a generalized Wilcoxon test. **: p < 0.01. (C)
Western blot analysis of Iba-1 shows markedly increased expression in lumbar spinal cord of mSOD1/RAG2-/- mice compared with mSOD1/RAG2
+/+ mice at early stage. Data presented in A-C is representative of three animals.
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+/+ mice at early stage but not at end stage disease. The
expression of IL-4R and IL-13 mRNA tended to be ele-
vated in the mSOD1/RAG2-/- mice at the early stage,
although this change was not significant (Figure 4A). In
contrast, levels of M1 microglia-related molecules such
as GM-CSF, IFN-g,I F N - g Ra n dN O S 2w e r es i m i l a r
between mSOD1/RAG2-/- mice and control mice both
at early and end stages (Figure 4B). It is worthy to note
that considerable expression of GM-CSF, which can
induce M1 microglia/macrophages, was observed at the
end stage of disease in both groups. There were no
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Figure 3 The number of GFAP-positive cells in spinal cord does not differ between mSOD1/RAG2+/+ and mSOD1/RAG2-/- mice.( A )
Lumbar sections of spinal cord from mSOD1/RAG2-/- mice and control mice stained with anti-GFAP antibody. Scale bar = 50 μm. (B) The
number of GFAP-positive astrocytes in lumbar cord of mSOD1/RAG2-/- mice does not significantly differ from that of control mSOD1 mice at
early (70-90 days of age) and end (130-150 days of age) stages. Data presented in A-B is representative of three animals.
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Figure 4 Expression of Ym1 mRNA is significantly increased in the spinal cord of mSOD1/RAG2-/- mice. Quantitative RT-PCR analyses of
spinal cord of mSOD1/RAG2-/- mice and mSOD1/RAG2+/+ mice at early (70-90 days of age) and end (130-150 days of age) stages were
performed (n = 3-4 in each group). (A) Relative mRNA expression of M-CSF, IL-4, IL-4R, IL-13, IL-13R, Retnla, and Ym1, which are related to M2
macrophages, is shown. Ym1 expression levels are significantly increased in mSOD1-RAG2-/- mice at the early stage of disease (p = 0.039). (B)
Relative mRNA expression of GM-CSF, IFN-g, IFN-g R, and NOS2, which are related to M1 macrophages, is shown. M1 macrophage-related
molecules were comparable between mSOD1/RAG2-/- mice and control mice. (C) Relative mRNA expression of GDNF and SLC1A3 is shown.
Expression levels of GDNF and SLC1A3 did not differ between mSOD1/RAG2-/- mice and control mice at early and end stages. Significance was
evaluated using the student’s t test. *: p < 0.05.
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neurotrophic factors such as GDNF and SLC1A3
between the two groups (Figure 4C). These results sug-
gest that M2 microglia are more dominant than M1
microglia in the spinal cord of mSOD1/RAG2-/- mice at
the early stage.
Discussion
In this study, we demonstrate delayed clinical onset in
mSOD1/RAG2-/- mice compared to mSOD1/RAG2+/+
mice, with increased number of activated microglia in
the spinal cord. Microgliosis in mSOD1/RAG2-/- mice
was accompanied by increased Ym1 mRNA expression,
one of the hallmarks of M2 microglia/macrophages.
However, the differences in weakness, microgliosis, and
Ym1 expression between SOD1/RAG2-/- and mSOD1/
RAG2+/+ mice disappeared in the later stage of disease.
This suggests that this affect on M2 microglia/macro-
phages, as the result of lymphocyte depletion, may be
associated with delayed clinical onset in mSOD1/
RAG2-/- mice. As a previous study has shown that B
lymphocytes do not have a major role in neurodegenera-
tion in G93A-SOD1 mice [15], T lymphocytes rather
than B lymphocytes are thought to be responsible for
the increased M2 activation of microglia. Although few
T lymphocytes have been shown to infiltrate spinal cord
i nm S O D 1m i c ei nt h ee a r l ys t a g e ,Tc e l l si nt h e
m e n i n g e sm a yh a v es o m ee f f e c t so nn e u r o n so rg l i a l
cells without entering the parenchyma [16-18].
Increased GM-CSF at the late stage of disease, as shown
in Figure 4B, might counteract the neuroprotective
effect of M2 microglia observed at the early phase.
In contrast to our finding of a deleterious effect of
lymphocytes in ALS, previous studies with mSOD1/
RAG2-/- mice have indicated a protective rather than
deleterious role of lymphocytes in mSOD1 mice
[6,16,19]. A possible explanation for these discrepancies
is differences in transgene copy number in the mice
used by us and other research groups. The mutant
G93A transgene is reported to undergo a background
level of copy loss due to meiotic rearrangement of the
transgene array [20,21]. Since mSOD1 has been sug-
gested to activate innate immunity downstream of the
toll-like receptor (TLR) 2, TLR4 and CD14 [22], a differ-
ence in transgene copy number may cause different
levels of microglial activation. Another possibility is
environmental factors. Mice maintained under germ-
free conditions develop significantly attenuated symp-
toms of experimental autoimmune encephalomyelitis
(EAE) compared with conventionally colonized mice,
and microbiota are reported to have an effect on the T-
helper/Treg axis outside of the gut [23]. Thus, different
microbiota of mice maintained in different facilities
could change the characteristics of lymphocytes and
other immune cells in the CNS, thus leading to the dis-
crepancy between our study and previous reports.
Piecing together our results and previous studies sug-
gests that lymphocytes might have biphasic effects on
neurons in this animal model of ALS. That is, lympho-
cytes may have a deleterious effect in the early phase of
neurodegeneration by suppressing M2 microglia,
whereas they may exert neuroprotective effects in the
later stage of the disease, thus leading to the shortened
survival of mSOD1/RAG2-/- mice reported in a pre-
vious study [6]. Transgene copy number of our mice
and the SPF condition of our facilities might be respon-
sible for the apparent difference seen in the early stage
of neurodegeneration between the two groups, while
those of other facilities appear to affect the end stage.
The present findings suggest that mature lymphocytes
act to produce a deterioration of the ALS phenotype in
mSOD1 mice at the early stage of the disease by modu-
lating the trophic balance of microglia. If the course of
ALS is so modulated, then disease progression could be
delayed by expanding populations of M2 microglia/
macrophages, thus producing neuroprotective effects.
Conclusions
This study reports delayed onset of ALS phenotype in
mSOD1/RAG2-/- mice compared to controls. We
observed an increased number of lectin-positive micro-
glia/macrophages at the ear l ys t a g eo fd i s e a s ei n
mSOD1/RAG2-/- mice compared with mSOD1/RAG2
+/+ mice. In addition, quantitative RT-PCR revealed
increased expression of mRNA for M2-microglial-
related genes in mSOD1/RAG2-/- mice. In conclusion,
these results indicate that peripheral lymphocytes act to
p r o d u c ead e t e r i o r a t i o no ft h eA L Sp h e n o t y p ei n
mSOD1 transgenic mice at the early stage of disease by
inhibiting M2 microglia/macrophage skewing.
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